Acquisition will bring together two companies committed to improving the lives of cancer patients through the evolving field of health data and analytics.
Under the deal, Accenture will provide digital data integration services to Roche's NAVIFY Tumor Board solution.
Called BiliScreen, it relies on computer vision algorithms and machine learning tools to detect increased bilirubin levels in a person's sclera.
The Sunface app photoages the user's skin based on skin type and individual UV-protection behavior.
The device uses two hundred small tactile biosensors that map the surface of the breast and monitor changes in texture, color and temperature.
One of the app features helps to manage, and track appointments, treatments, goals, tips, information, and what has worked for others in similar situations.
The Breast Cancer Weight Loss (BWEL) study will enroll nearly 3,200 overweight and obese women with early stage breast cancer.
The company's will license American Cancer Society's care guidance so that its Care Pros can give specialized care to clients diagnosed with cancer.
Researchers want to use the activity tracker to determine if it can help oncologists assess whether their patients are active enough for chemotherapy.
Called Breast Cancer Ally, the application was developed after gathering feedback from both specialists who cared for patients and patients themselves.